Novaliq develops and commercializes ocular therapeutics built on EyeSol®, the world’s first water-free technology for ophthalmology. Its lead late-stage assets are CyclASol® (an anti-inflammatory and immunomodulating drug in the pivotal phase 2b/3 ESSENCE trial) and NOV03 (a first-in-class treatment for evaporative dry eye disease associated with meibomian gland dysfunction, in the phase 2 SEECASE trial with more than 300 patients). Both products target different dry eye disease patient groups and are estimated to have global peak sales well above USD 2 billion. Novaliq also markets NovaTears® (sold as EvoTears® in Europe) and maintains earlier pipeline programs for glaucoma and retinal diseases. The company is headquartered in Heidelberg, Germany, with an office in Cambridge, MA. Proceeds from the financing will be used to fund clinical development, prepare commercialization of CyclASol® and NOV03, and advance earlier pipeline programs. The long-term shareholder and lead investor is dievini Hopp BioTech Holding. Novaliq develops ocular formulations using patented semifluorinated alkanes (SFAs) and its EyeSol™ technology to deliver preservative-free topical eye drops. Its lead prescription candidate, CyclASol, is presented as the first cyclosporine A solution for dry eye disease. The company’s strategy is to build a portfolio of consumer and prescription products targeting evaporative dry eye, emphasizing preservative-free, surfactant-free multidose formulations for improved tolerability. Novaliq also pursues other product candidates and solutions for organ preservation, leveraging SFAs’ properties for drug and oxygen transport across routes of administration. The company plans to advance lead projects into the medical device field for approval, progress CyclASol into clinical development, and extend its technology platform. Novaliq is headquartered in Heidelberg, Germany.

Total raised

$71M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2018